Serina (SER) - Debt to Book Capitalization Ratio

Serina Therapeutics, Inc. (SER) is developing a scalable licensing model for polymer gene delivery systems tailored for third-party pharma behemoths. The current debt-to-equity ratio illustrates the financial leverage, where the 0.16 metric reflects the current trend. Stability is maintained by retaining leading neurobiologists through stock options, while the environmental strategy is based on minimizing chemical waste while adhering to strict bioethics.

Serina Therapeutics, Inc. (SER) focuses on the clinical development of drug delivery systems and is entirely dependent on external financing. The history of changes in the debt-to-equity ratio reflects the company's degree of reliance on borrowed funds relative to its own equity. This ratio serves as a mathematical filter for calculating the Sharpe ratio during periods of sharp volatility. Reducing the debt load minimizes the risk of an asset collapse but limits overall returns. Negative cash flow makes this indicator a key measure of the business's financial stability.